Literature DB >> 31385161

Variations in actual practice patterns and their deviations from the clinical practice guidelines for nephrotic syndrome in Japan: certified nephrologists' questionnaire survey.

Kakuya Niihata1,2, Hiroki Nishiwaki2,3, Noriaki Kurita4,5,6, Hirokazu Okada7, Shoichi Maruyama8, Ichiei Narita9, Yugo Shibagaki10, Izaya Nakaya11.   

Abstract

BACKGROUND: Few good-quality clinical trials on adults with nephrotic syndrome exist. Thus, there are discrepancies between real-world practice and clinical practice guidelines. We conducted a questionnaire-based survey to investigate potential discrepancies and the factors associated with variations in clinical practice.
METHODS: A questionnaire was administered electronically to all board-certified nephrologists in Japan. To examine clinical practice variations in relation to physician characteristics, we estimated the ratio of the mean duration of steroid therapy using a generalized linear model, and the odds ratio of higher level ordinal variables using an ordered logistic regression model.
RESULTS: Responses of the 116 participants showed some variation for the majority of questions. Most participants (94.8%) indicated that screening for malignant tumors was "Conducted for almost all patients". The duration of steroid therapy was found to be longer among physicians seeing ≥ 30 patients with nephrotic syndrome per month, both for minimal-change disease (ratio of mean 1.69; 95% CI 1.07-2.66) and membranous nephropathy (ratio of mean 1.71; 95% CI 1.09-2.69).
CONCLUSIONS: We identified practice patterns for nephrotic syndrome and discrepancies between clinical practice guidelines and actual practice. Defining the standard therapy for nephrotic syndrome may be necessary to generate high-quality evidence and develop clinical guidelines.

Entities:  

Keywords:  Guideline-practice gap; Nephrotic syndrome; Practice patterns

Mesh:

Substances:

Year:  2019        PMID: 31385161     DOI: 10.1007/s10157-019-01772-z

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  7 in total

1.  [JSN and MHLW Clinical Practice Guideline for Nephrotic Syndrome 2014].

Authors: 
Journal:  Nihon Jinzo Gakkai Shi       Date:  2014

2.  Age and prediction of remission and relapse of proteinuria and corticosteroid-related adverse events in adult-onset minimal-change disease: a retrospective cohort study.

Authors:  Maki Shinzawa; Ryohei Yamamoto; Yasuyuki Nagasawa; Susumu Oseto; Daisuke Mori; Kodo Tomida; Terumasa Hayashi; Masaaki Izumi; Megumu Fukunaga; Atsushi Yamauchi; Yoshiharu Tsubakihara; Hiromi Rakugi; Yoshitaka Isaka
Journal:  Clin Exp Nephrol       Date:  2013-03-20       Impact factor: 2.801

3.  ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients.

Authors:  Johan Maertens; Simone Cesaro; Georg Maschmeyer; Hermann Einsele; J Peter Donnelly; Alexandre Alanio; Philippe M Hauser; Katrien Lagrou; Willem J G Melchers; Jannik Helweg-Larsen; Olga Matos; Stéphane Bretagne; Catherine Cordonnier
Journal:  J Antimicrob Chemother       Date:  2016-05-12       Impact factor: 5.790

4.  A survey of rheumatologists' practice for prescribing pneumocystis prophylaxis.

Authors:  Deanna Cettomai; Allan C Gelber; Lisa Christopher-Stine
Journal:  J Rheumatol       Date:  2010-03-01       Impact factor: 4.666

5.  Comparison of methylprednisolone plus prednisolone with prednisolone alone as initial treatment in adult-onset minimal change disease: a retrospective cohort study.

Authors:  Maki Shinzawa; Ryohei Yamamoto; Yasuyuki Nagasawa; Susumu Oseto; Daisuke Mori; Kodo Tomida; Terumasa Hayashi; Masaaki Izumi; Megumu Fukunaga; Atsushi Yamauchi; Yoshiharu Tsubakihara; Yoshitaka Isaka
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

6.  Effective and safe treatment with cyclosporine in nephrotic children: a prospective, randomized multicenter trial.

Authors:  K Ishikura; M Ikeda; S Hattori; N Yoshikawa; S Sasaki; K Iijima; K Nakanishi; N Yata; M Honda
Journal:  Kidney Int       Date:  2008-02-27       Impact factor: 10.612

7.  A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatment.

Authors:  Norishige Yoshikawa; Koichi Nakanishi; Mayumi Sako; Mari S Oba; Rintaro Mori; Erika Ota; Kenji Ishikura; Hiroshi Hataya; Masataka Honda; Shuichi Ito; Yuko Shima; Hiroshi Kaito; Kandai Nozu; Hidefumi Nakamura; Takashi Igarashi; Yasuo Ohashi; Kazumoto Iijima
Journal:  Kidney Int       Date:  2014-07-23       Impact factor: 10.612

  7 in total
  2 in total

1.  Time to remission of proteinuria and incidence of relapse in patients with steroid-sensitive minimal change disease and focal segmental glomerulosclerosis: the Japan Nephrotic Syndrome Cohort Study.

Authors:  Ryohei Yamamoto; Enyu Imai; Shoichi Maruyama; Hitoshi Yokoyama; Hitoshi Sugiyama; Asami Takeda; Tatsuo Tsukamoto; Shunya Uchida; Kazuhiko Tsuruya; Tatsuya Shoji; Hiroki Hayashi; Yasuhiro Akai; Megumu Fukunaga; Tsuneo Konta; Saori Nishio; Shunsuke Goto; Hirofumi Tamai; Kojiro Nagai; Ritsuko Katafuchi; Kosuke Masutani; Takashi Wada; Tomoya Nishino; Arimasa Shirasaki; Hiroshi Sobajima; Kosaku Nitta; Kunihiro Yamagata; Junichiro J Kazama; Keiju Hiromura; Hideo Yasuda; Makoto Mizutani; Toshiyuki Akahori; Tomohiko Naruse; Takeyuki Hiramatsu; Kunio Morozumi; Tetsushi Mimura; Yosuke Saka; Eiji Ishimura; Hajime Hasegawa; Daisuke Ichikawa; Takashi Shigematsu; Hiroshi Sato; Ichiei Narita; Yoshitaka Isaka
Journal:  J Nephrol       Date:  2022-04-02       Impact factor: 3.902

2.  Incidence and factors associated with prescribing renin-angiotensin-system inhibitors in adult idiopathic nephrotic syndrome: A nationwide cohort study.

Authors:  Hiroki Nishiwaki; Kakuya Niihata; Sayaka Shimizu; Yugo Shibagaki; Ryohei Yamamoto; Kosaku Nitta; Tatsuo Tsukamoto; Shunya Uchida; Asami Takeda; Hirokazu Okada; Ichiei Narita; Yoshitaka Isaka; Noriaki Kurita
Journal:  J Clin Hypertens (Greenwich)       Date:  2021-03-01       Impact factor: 3.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.